Skip to main content
Camlin Fine Sciences Ltd logo

Camlin Fine Sciences Ltd — Investor Relations & Filings

Ticker · CAMLINFINE ISIN · INE052I01032 LEI · 3358005CR8R9MY6DLY36 BSE.NS Manufacturing
Open in API
Filings indexed 1,525 across all filing types
Latest filing 2019-05-23 Call Transcript
Country IN India
Listing BSE.NS CAMLINFINE

About Camlin Fine Sciences Ltd

https://www.camlinfs.com

Camlin Fine Sciences Ltd is a global provider of specialty chemicals, specializing in shelf-life extension solutions and aroma ingredients. The company is a leading manufacturer of traditional antioxidants, including Tertiary Butylhydroquinone (TBHQ) and Butylated Hydroxyanisole (BHA), which are utilized to maintain the stability and quality of food, feed, and industrial applications. Its product portfolio also features aroma chemicals such as vanillin and ethyl vanillin, supported by a vertically integrated manufacturing process. Camlin Fine Sciences serves a broad range of sectors, including human nutrition, animal health, pet food, pharmaceuticals, and fragrances. By utilizing advanced chemical synthesis and a global distribution network, the company delivers performance chemicals and customized blends designed to enhance product longevity and sensory characteristics.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is a notification to stock exchanges about a scheduled conference call with investors and analysts to discuss the financial results for the quarter ended 31 March 2019 (Q4). It includes details such as date, time, participants, and dial-in numbers for the call. The document does not contain actual financial statements or detailed financial analysis but is an announcement of the upcoming earnings call event. According to the classification rules, such a document is best classified as a Call Transcript (CT) if it contained the full transcript, but since this is only an announcement of the call, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement. However, since the document is specifically about the conference call event, the best fitting category is Call Transcript (CT) as it relates directly to the earnings call event, even though it is only the announcement and not the transcript itself. Given the document length and content, confidence is high but not absolute because it is an announcement rather than the transcript itself.
2019-05-23 English
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period ....
Regulatory Filings
2019-05-22 English
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Subhash Dandekar
Regulatory Filings
2019-05-17 English
Amalgamation/Merger
Regulatory Filings Classification · 95% confidence The document is an intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about a reverse merger between subsidiaries of the company. It provides details about the merger, rationale, and related information as per SEBI disclosure requirements. There are no financial statements or detailed financial performance data, nor is it a full report or presentation. The document is an official announcement of a corporate event (merger) relevant to shareholders and regulators. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and compliance document that does not fit into more specific categories like M&A filings or Annual Reports.
2019-05-08 English
Merger of Subsidiaries
Regulatory Filings
2019-05-08 English
Press Release
Regulatory Filings
2019-05-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.